Second CAR T-Cell Infusion Hits Myeloma After CELMoD Bridging
A German case report describes rapid deep response to ciltacabtagene autoleucel as a second BCMA-directed CAR T-cell therapy after mezigdomide-based ...
A German case report describes rapid deep response to ciltacabtagene autoleucel as a second BCMA-directed CAR T-cell therapy after mezigdomide-based ...
In the evolving landscape of multiple myeloma treatment, researchers are pursuing novel therapies to enhance patient outcomes, particularly for those ...
In recent years, the landscape of treatment options for multiple myeloma has undergone a profound transformation, particularly with the advent ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine